These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 27184830

  • 1. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective.
    Bobin P, Belacel-Ouari M, Bedioune I, Zhang L, Leroy J, Leblais V, Fischmeister R, Vandecasteele G.
    Arch Cardiovasc Dis; 2016; 109(6-7):431-43. PubMed ID: 27184830
    [Abstract] [Full Text] [Related]

  • 2. [Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives].
    Bedioune I, Bobin P, Karam S, Lindner M, Mika D, Lechêne P, Leroy J, Fischmeister R, Vandecasteele G.
    Biol Aujourdhui; 2016; 210(3):127-138. PubMed ID: 27813474
    [Abstract] [Full Text] [Related]

  • 3. Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications.
    Miller CL, Yan C.
    J Cardiovasc Transl Res; 2010 Oct; 3(5):507-15. PubMed ID: 20632220
    [Abstract] [Full Text] [Related]

  • 4. Myocardial Phosphodiesterases and Their Role in cGMP Regulation.
    Dunkerly-Eyring B, Kass DA.
    J Cardiovasc Pharmacol; 2020 Jun; 75(6):483-493. PubMed ID: 31651671
    [Abstract] [Full Text] [Related]

  • 5. [Phosphodiesterase regulation of cardiovascular functions].
    Li L, He Q, Gao YS.
    Sheng Li Ke Xue Jin Zhan; 2010 Apr; 41(2):100-6. PubMed ID: 21416994
    [Abstract] [Full Text] [Related]

  • 6. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):110-7. PubMed ID: 16458289
    [Abstract] [Full Text] [Related]

  • 7. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.
    Kamel R, Leroy J, Vandecasteele G, Fischmeister R.
    Nat Rev Cardiol; 2023 Feb 08; 20(2):90-108. PubMed ID: 36050457
    [Abstract] [Full Text] [Related]

  • 8. Cyclic nucleotide signalling compartmentation by PDEs in cultured vascular smooth muscle cells.
    Zhang L, Bouadjel K, Manoury B, Vandecasteele G, Fischmeister R, Leblais V.
    Br J Pharmacol; 2019 Jun 08; 176(11):1780-1792. PubMed ID: 30825186
    [Abstract] [Full Text] [Related]

  • 9. Nanodomain Regulation of Cardiac Cyclic Nucleotide Signaling by Phosphodiesterases.
    Kokkonen K, Kass DA.
    Annu Rev Pharmacol Toxicol; 2017 Jan 06; 57():455-479. PubMed ID: 27732797
    [Abstract] [Full Text] [Related]

  • 10. PDE2 at the crossway between cAMP and cGMP signalling in the heart.
    Weber S, Zeller M, Guan K, Wunder F, Wagner M, El-Armouche A.
    Cell Signal; 2017 Oct 06; 38():76-84. PubMed ID: 28668721
    [Abstract] [Full Text] [Related]

  • 11. [Cyclic nucleotide phosphodiesterases: therapeutic targets in cardiac hypertrophy and failure].
    Barthou A, Kamel R, Leroy J, Vandecasteele G, Fischmeister R.
    Med Sci (Paris); 2024 Oct 06; 40(6-7):534-543. PubMed ID: 38986098
    [Abstract] [Full Text] [Related]

  • 12. Phosphodiesterases in the vascular system.
    Matsumoto T, Kobayashi T, Kamata K.
    J Smooth Muscle Res; 2003 Aug 06; 39(4):67-86. PubMed ID: 14692693
    [Abstract] [Full Text] [Related]

  • 13. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J, Grande JP.
    Exp Biol Med (Maywood); 2007 Jan 06; 232(1):38-51. PubMed ID: 17202584
    [Abstract] [Full Text] [Related]

  • 14. Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease.
    Osadchii OE.
    Cardiovasc Drugs Ther; 2007 Jun 06; 21(3):171-94. PubMed ID: 17373584
    [Abstract] [Full Text] [Related]

  • 15. Regulation of murine cardiac function by phosphodiesterases type 3 and 4.
    Beca S, Aschars-Sobbi R, Panama BK, Backx PH.
    Curr Opin Pharmacol; 2011 Dec 06; 11(6):714-9. PubMed ID: 22047792
    [Abstract] [Full Text] [Related]

  • 16. An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases.
    Chen S, Yan C.
    Expert Opin Drug Discov; 2021 Feb 06; 16(2):183-196. PubMed ID: 32957823
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular implications in the use of PDE5 inhibitor therapy.
    Maurice DH.
    Int J Impot Res; 2004 Jun 06; 16 Suppl 1():S20-3. PubMed ID: 15224131
    [Abstract] [Full Text] [Related]

  • 18. Immunohistochemical distribution of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human vagina: a potential forensic value?
    Albrecht K, Uckert S, Oelke M, Andersson KE, Jonas U, Tröger HD, Hedlund P.
    J Forensic Leg Med; 2007 Jul 06; 14(5):270-4. PubMed ID: 17113813
    [Abstract] [Full Text] [Related]

  • 19. Cyclic nucleotide phosphodiesterases and vascular smooth muscle.
    Polson JB, Strada SJ.
    Annu Rev Pharmacol Toxicol; 1996 Jul 06; 36():403-27. PubMed ID: 8725396
    [Abstract] [Full Text] [Related]

  • 20. Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.
    Preedy MEJ.
    Cardiovasc Drugs Ther; 2020 Jun 06; 34(3):401-417. PubMed ID: 32172427
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.